In a long-term study of Canadian surveillance data researchers found that immunocompromised people were at a 12-fold risk of invasive pneumococcal disease (IPD) compared to healthy people. In addition, the risk of death from IPD in immunocompromised people was found to be 30-80% higher than healthy individuals who had contracted IPD. 10 years after introduction of PCV7 in Canada, the incidence of IPD due to serotypes included in the vaccine had decreased by 90%.
Full Citation:
Shigayeva, A., Rudnick, W., Green, K., et al. 2016. Invasive pneumococcal disease among immunocompromised persons: implications for vaccination programs. Clinical Infectious Disease. 62(2).
Title of Article: Invasive pneumococcal disease among immunocompromised persons: implications for vaccination programs
Author(s): Shigayeva, A., Rudnick, W., Green, K., et al
Publication Year: 2016
Publication Name: Clinical Infectious Disease
Publication Volume: 62(2)
Publication Source URL: https://pubmed.ncbi.nlm.nih.gov/26354970/
DOI (Digital Object Identifier): 10.1093/cid/civ803
Topics: Health
Disease Vaccines: Pneumococcal disease/PCV/PPSV | Pneumonia
Countries: Canada
WHO Regions: Americas